Nothing Special   »   [go: up one dir, main page]

WO2004087956A3 - Cell lines for the functional expression of nav1.8 - Google Patents

Cell lines for the functional expression of nav1.8 Download PDF

Info

Publication number
WO2004087956A3
WO2004087956A3 PCT/GB2004/001458 GB2004001458W WO2004087956A3 WO 2004087956 A3 WO2004087956 A3 WO 2004087956A3 GB 2004001458 W GB2004001458 W GB 2004001458W WO 2004087956 A3 WO2004087956 A3 WO 2004087956A3
Authority
WO
WIPO (PCT)
Prior art keywords
nav
channel
utr
cell
activity
Prior art date
Application number
PCT/GB2004/001458
Other languages
French (fr)
Other versions
WO2004087956A2 (en
Inventor
Lodewijk Victor Dekker
Iain Fraser James
Original Assignee
Ionix Pharmaceuticals Ltd
Lodewijk Victor Dekker
Iain Fraser James
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0307633A external-priority patent/GB0307633D0/en
Priority claimed from GB0307632A external-priority patent/GB0307632D0/en
Application filed by Ionix Pharmaceuticals Ltd, Lodewijk Victor Dekker, Iain Fraser James filed Critical Ionix Pharmaceuticals Ltd
Publication of WO2004087956A2 publication Critical patent/WO2004087956A2/en
Publication of WO2004087956A3 publication Critical patent/WO2004087956A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to cell lines that express functional Nav 1.8 sodium channels. In particular, the invention relates to a method of identifying a modulator of a Nav 1.8 channel, which method comprises: (a) bringing into contact a test compound and a cell comprising a heterologous nucleic acid having a sequence which encodes a Nav1.8 channel, wherein the heterologous nucleic acid comprises the 3' and/or 5' untranslated region (UTR) of a Nav 1.8 gene or a functional variant of the 3' and/or 5' UTR of a Nav 1.8 gene, said UTR or variant UTR being operably linked to the region encoding the Nav 1.8 channel and wherein the cell expresses p 11 from an endogenous gene at a sufficient level to allow a Nav 1.8 channel expressed from said heterologous nucleic acid to mediate a sodium current across a membrane of the cell; and (b) measuring an activity of the Nav 1.8 channel, wherein a change in the activity of the channel relative to the activity in the absence of the test compound indicates that the test compound is a modulator of the Nav 1.8 channel.
PCT/GB2004/001458 2003-04-02 2004-04-02 Cell lines for the functional expression of nav1.8 WO2004087956A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0307633A GB0307633D0 (en) 2003-04-02 2003-04-02 Chemical compounds
GB0307632A GB0307632D0 (en) 2003-04-02 2003-04-02 Chemical compounds
GB0307632.0 2003-04-02
GB0307633.8 2003-04-02
US47557003P 2003-06-04 2003-06-04
US60/475,570 2003-06-04
US48573003P 2003-07-10 2003-07-10
US48573503P 2003-07-10 2003-07-10
US60/485,730 2003-07-10
US60/485,735 2003-07-10

Publications (2)

Publication Number Publication Date
WO2004087956A2 WO2004087956A2 (en) 2004-10-14
WO2004087956A3 true WO2004087956A3 (en) 2005-03-03

Family

ID=32303749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001458 WO2004087956A2 (en) 2003-04-02 2004-04-02 Cell lines for the functional expression of nav1.8

Country Status (2)

Country Link
GB (1) GB2400103A (en)
WO (1) WO2004087956A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051829A1 (en) * 2004-10-27 2007-02-14 Schering Corp COMPOSITIONS AND METHODS FOR NAV INHIBITION 1 THROUGH SHORT ARN INTERFERENCE
WO2007056326A2 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
FR3007762B1 (en) * 2013-06-28 2015-09-04 Galderma Res & Dev ANTIBODIES AGAINST THE HUMAN NAV1.9 SODIUM CHANNEL AND THEIR USES FOR THE DIAGNOSIS OF INFLAMMATORY SKIN DISEASES
FR3007656B1 (en) * 2013-06-28 2015-06-26 Galderma Res & Dev MODULATORS OF THE NAV1.9 SODIUM CHANNEL FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASE AND DIAGNOSTIC METHODS
FR3007763A1 (en) * 2013-06-28 2015-01-02 Galderma Res & Dev ANTIBODIES AGAINST THE HUMAN NAV1.9 SODIUM CHANNEL AND THEIR USES IN DIAGNOSIS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044293A2 (en) * 1999-12-17 2001-06-21 Glaxo Group Limited Sodium channel proteins
WO2001068681A2 (en) * 2000-03-14 2001-09-20 Glaxo Group Limited Altered ion channel proteins
DE10054878A1 (en) * 2000-11-06 2002-05-08 Boehringer Ingelheim Int Peripheral nerve type sodium channels
WO2003006103A2 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Electrical field stimulation of eukaryotic cells
WO2003016917A2 (en) * 2001-08-20 2003-02-27 University College London Sodium channel regulators and modulators
WO2003037900A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513180D0 (en) * 1995-06-28 1995-08-30 Univ London Ion channel
US6184349B1 (en) * 1995-10-11 2001-02-06 Syntex (Usa) Inc. Cloned peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit
US7256001B2 (en) * 2001-08-17 2007-08-14 Eisai R&D Management Co., Ltd. Reagent for determining laminin 5 antigen in biological sample and assay method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044293A2 (en) * 1999-12-17 2001-06-21 Glaxo Group Limited Sodium channel proteins
WO2001068681A2 (en) * 2000-03-14 2001-09-20 Glaxo Group Limited Altered ion channel proteins
DE10054878A1 (en) * 2000-11-06 2002-05-08 Boehringer Ingelheim Int Peripheral nerve type sodium channels
WO2003006103A2 (en) * 2001-07-12 2003-01-23 Merck & Co., Inc. Electrical field stimulation of eukaryotic cells
WO2003016917A2 (en) * 2001-08-20 2003-02-27 University College London Sodium channel regulators and modulators
WO2003037900A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIRCH P J ET AL: "Strategies to identify ion channel modulators: Current and novel approaches to target neuropathic pain", DRUG DISCOVERY TODAY 01 MAY 2004 UNITED KINGDOM, vol. 9, no. 9, 1 May 2004 (2004-05-01), pages 410 - 418, XP002295892, ISSN: 1359-6446 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002, ZHOU X ET AL: "VINPOCETINE, A POTENT AND USE-DEPENDENT BLOCKER OF TTX-RESISTANT NAV1.8 SODIUM CHANNELS.", XP002300610, Database accession no. PREV200300326329 *
DATABASE EMBL EBI; 29 December 2002 (2002-12-29), "Homo sapiens 3 BAC RP11-1114A3, complete sequence", XP002295894, Database accession no. AC137625 *
DATABASE EMBL EBI; 29 June 2002 (2002-06-29), "Homo sapiens chromosome 3 clone RP11-134J21", XP002295893, Database accession no. AC116038 *
JOHN VICTORIA H ET AL: "Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23.", NEUROPHARMACOLOGY. MAR 2004, vol. 46, no. 3, March 2004 (2004-03-01), pages 425 - 438, XP002295891, ISSN: 0028-3908 *
OKUSE K ET AL: "ANNEXIN II LIGHT CHAIN REGULATES SENSORY NEURON-SPECIFIC SODIUM CHANNEL EXPRESSION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 417, no. 6889, 6 June 2002 (2002-06-06), pages 653 - 656, XP001121255, ISSN: 0028-0836 *
RABERT DOUGLAS K ET AL: "A tetrodotoxin-resistant voltage-gated sodium channel from human dorsal root ganglia, hPN3/SCN10A", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 78, no. 2, November 1998 (1998-11-01), pages 107 - 114, XP002198530, ISSN: 0304-3959 *
SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 743.15 URL - http://sf *
ZHOU XIAOPING ET AL: "Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. AUG 2003, vol. 306, no. 2, August 2003 (2003-08-01), pages 498 - 504, XP002295890, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
GB2400103A (en) 2004-10-06
WO2004087956A2 (en) 2004-10-14
GB0407620D0 (en) 2004-05-05

Similar Documents

Publication Publication Date Title
ATE405586T1 (en) METHOD FOR REGULATING IMMUNE FUNCTION IN PRIMATES USING THE FOXP3 PROTEIN
WO2004081174A3 (en) Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
HK1099938A1 (en) Gene expression technique
WO1999063101A3 (en) Transfected cells and methods for treating diabetes
WO1999036516A3 (en) Method of determining the function of nucleotide sequences and the proteins they encode by transfecting the same into a host
WO2003046186A8 (en) siRNA EXPRESSION SYSTEM AND METHOD FOR PRODUCING FUNCTIONAL GENE KNOCK-DOWN CELLS USING THE SYSTEM
ATE440961T1 (en) MESENCHYMAL STEM CELLS AS A VEHICLE FOR ION CHANNEL TRANSFER IN SYNZYTIC STRUCTURES
WO2002103046A3 (en) Happier mapping
DE10345772A1 (en) Process for the preparation of 3-methylamino-1- (thien-2-yl) -propan-1-ol
ATE317899T1 (en) ANTI-FREEZE PROTEINS FROM CHORISTONEURA SP., GENES AND METHODS FOR THEIR USE
WO2004087956A3 (en) Cell lines for the functional expression of nav1.8
AU2003238717A1 (en) POLYPEPTIDES HAVING Alpha- H-Alpha-AMINO ACID AMIDE RACEMASE ACTIVITY AND NUCLEIC ACIDS ENCODING THE SAME
WO1996007739A3 (en) Interleukin-1 type 3 receptors
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2002022826A3 (en) Methods and compositions for the construction and use of fusion libraries
WO1999047686A3 (en) Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
WO2003016917A3 (en) Sodium channel regulators and modulators
WO2002079507A3 (en) Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
EP0962530A3 (en) Gene sequence encoding for the angiopoietin related protein scarface 1
EP4276191A3 (en) Multi-copy gene protein expression system
DE60125653D1 (en) For phosphoglucomutases from Glycine max plastids encoding nucleic acids
WO2002087606A3 (en) Modulators of the hypocretin system and methods of screening therefor
WO2008073166A3 (en) Multi-variant cell indication technique
WO2004009835A3 (en) Method for identifying cellular growth inhibitors
WO2002064756A8 (en) Stem cell identification

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase